IMPORTANT
THE VIAL MAY SEEM EMPTY
−
AND THAT’S NORMAL!
WE INCLUDE ICE PACKS THAT MAY MELT DURING SHIPPING. HOWEVER, THE QUALITY OF THE PRODUCTS IS NOT COMPROMISED, AS BRIEF TEMPERATURE CHANGES DO NOT AFFECT THEIR EFFECTIVENESS AND SAFETY
Proven Efficacy & Safety
The efficacy and the Safety of Meditoxin® are proved to be comparable to OnabotulinumtoxinA in various clinical studies.
I. Glabellar Frown Lines
Comparative clinical study for Glabellar Frown Lines with Meditoxin® vs. OnabotulinumtoxinA1
Percentage of responder based on physician’s live assessment
Methodology
Multi-center, double blinded, randomized, active controlled, parallel designed, phase Ill clinical study.
Subjects
314 healthy adult patients(aged between 20 to 65) with moderate or severe glabellar lines at maximum frown.
Results
The efficacy of Meditoxin® was not inferior to that of Onabotulinumtoxin A.
No difference was noted in the frequency of adverse events. Meditoxin® can be safely used as an alternative to botox treatment at an equivalent ratio of 1:1.
- Adverse Event Rate(%)
The common (>1%) treatment-related AEs were eyeliaptosis (5/156, 3.2% NBoNT group; 3/157, 1.9% OBoNT group) and extraocularmuscle disorder (1/156, 0.6% NBoNT group; 4/157, 2.6% OBoNT group).
All other related AEs had a total incidence of <1%. No statistical differenes in the incidence and severity of AEs between the two groups were observed.
Reference 1.
CH Huh et al. Efficacy and Safety of a Novel Botulinum Toxin Type A Product for the Treatment of Moderate to Severe Glabellar Lines: A Randomized, Double-Blind, Active-Controlled Multicenter Study. Dermatol Surg
2013;39:171-178
II. Essential Blepharospasm
Comparative clinical study for Essential Blepharospasm with Meditoxin® vs. OnabotulinumtoxinA2
Methodology
Multi-center, double blinded, randomized, active controlled, parallel designed, phase Il clinical study.
Subjects
60 patients diagnosed with an essential blepharospasm.
(Meditoxin® n=31 / Botox® n=29)
Results
The efficacy of Meditoxin® was not inferior to Botox® in this clinical study. No difference was noted in the frequency of adverse events. Meditoxin® can be safely used as an alternative to botox treatment at an equivalent ratio of 1:1.
- Adverse Event Rate(%)
16.1% of patients(treated with Meditoxin) and 27.6% of patients(treated with OnabotulinumtoxinA) experienced adverse events. As the results did not show any significant differences between the two groups, they were proven to have similar safety profiles.
Reference 2.
Yoon JS et al. Double-Blind, Randomized, Comparative Study of Meditoxin® Versus Botox® in the Treatment of Essential Blepharospasm. Korean Journal of Ophthalmology 2009;23:137-141
World-wide Product
Meditoxin® is registered in 27 countries including Korea, Brazil, India, Hong Kong, Ukraine, Thailand and Mexico. Currently, it is in the process of registration in 30 additional countries.
Registered countries*
AZERBAIJAN
BOLIVIA
BRAZIL
CHILE
COLOMBIA
PARAGUAY
COSTARICA
DOMINICA REP
EL SALVADOR
GEORGIA
GUATEMALA
MEXICO
HONGKONG
INDIA
IRAN
KAZAKHSTAN
KOREA
KYRGYZSTAN
LEBANON
NICARAGUA
PANAMA
PERU
PHILIPPINES
THAILAND
UKRAINE
UZBEKISTAN
VIETNAM
Meditoxin® is also being sold worldwide under different brand names, as Siax®, Botulift®, Cunox® and Neuronox®.
Various Choice of products
Meditoxin® offers various choices according to the application.
Physicians find it easier to use and the patients more economical.
Related products
TOXINS
$95
TOXINS
$100
TOXINS
$85
TOXINS
$65
TOXINS
$52
TOXINS
$152
TOXINS
$95
TOXINS
$52
